Look up one drug

Matched class: 08:18 Antivirals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABACAVIR & LAMIVUDINE & ZIDOVUDINE, ABACAVIR SULFATE, ABACAVIR SULFATE & LAMIVUDINE, CABOTEGRAVIR, CABOTEGRAVIR & RILPIVIRINE, COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, DARUNAVIR & COBICISTAT, DELAVIRDINE MESYLATE, DOLUTEGRAVIR, DOLUTEGRAVIR & ABACAVIR & LAMIVUDINE, DOLUTEGRAVIR & RILPIVIRINE, DOLUTEGRAVIR SODIUM/LAMIVUDINE, DORAVIRINE, DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE, EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR DISOPROXIL, EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, ETRAVIRINE, FOSAMPRENAVIR CALCIUM, GANCICLOVIR SODIUM, LAMIVUDINE & ZIDOVUDINE, LOPINAVIR & RITONAVIR, MARAVIROC, NELFINAVIR MESYLATE, RALTEGRAVIR POTASSIUM, RILPIVIRINE HYDROCHLORIDE, RITONAVIR Some products covered without a code (check the product listing): ACYCLOVIR, ATAZANAVIR SULFATE, DARUNAVIR, EFAVIRENZ, LAMIVUDINE, NEVIRAPINE, VALACYCLOVIR 08:18 Antivirals

ABACAVIR SULFATE

· 4 products · General benefit · strengths: 20mg/mL, 300mg · O/L, Tab

LAMIVUDINE

· 10 products · General benefit (7), Listed, not a benefit (1), Limited Use, codes 502, 503, 504 (2) · strengths: 10mg/mL, 100mg, 150mg, 300mg · O/L, Tab

ENTECAVIR

· 8 products · Limited Use, codes 505, 506, 507, 508 · strengths: 0.5mg · Tab

TENOFOVIR DISOPROXIL

· 11 products · Limited Use, codes 517, 518, 519, 520, 521, 522 · strengths: 300mg · Tab

ADEFOVIR DIPIVOXIL

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg · Tab

ZIDOVUDINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg · Cap

ABACAVIR & LAMIVUDINE & ZIDOVUDINE

· 2 products · General benefit · strengths: 300mg & 150mg & 300mg · Tab

ABACAVIR SULFATE & LAMIVUDINE

· 7 products · General benefit · strengths: 600mg & 300mg · Tab

ACYCLOVIR

· 15 products · Listed, not a benefit (2), General benefit (13) · strengths: 200mg, 400mg, 800mg · Tab

ATAZANAVIR SULFATE

· 12 products · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (4) · strengths: 150mg, 200mg, 300mg · Cap

CABOTEGRAVIR

· 3 products · General benefit · strengths: 200mg/mL, 30mg · Inj Sol-ER Susp 3mL Vial Kit Pk, Tab

CABOTEGRAVIR & RILPIVIRINE

· 2 products · General benefit · strengths: 200mg/mL & 300mg/mL · Inj Sol-2mL Kit, Inj Sol-3mL Kit Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:18 and 38 more

From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR DISOPROXIL, ETRAVIRINE, RILPIVIRINE HYDROCHLORIDE ATAZANAVIR SULFATE · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (4) 1 INDICATIONS TEVA-ATAZANAVIR (atazanavir capsules) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults and pediatric patients 6 years of age and older weighing at least 20 kg. PM: https://pdf.hres.ca/dpd_pm/00078880.PDF; date April 18, 2017; DIN 02443791; fetched 2026-09-10 Product monograph DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE · General benefit 1 Indications DELSTRIGO® (doravirine/lamivudine/tenofovir disoproxil fumarate) is indicated as a complete regimen for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults and pediatric patients 12 years of age and older and weighing at least 35 kg without past or present evidence of viral resistance to doravirine, lamivudine, or tenofovir. 1.1 Pediatrics Pediatrics ( 12 to < 18 years of age): The safety and efficacy of DELSTRIGO® in pediatric patients 12 years of age and older and weighing at least 35 kg receiving DELSTRIGO® once daily have been established (see 8.2.1 Clinical Trial Adverse Reactions – Pediatrics and 14 Clinical trial). PM: https://pdf.hres.ca/dpd_pm/00081855.PDF; date not captured; DIN 02482592; fetched 2026-09-10 Product monograph EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR DISOPROXIL · General benefit INDICATIONS AND CLINICAL USE COMPLERA® (emtricitabine [FTC]/rilpivirine [RPV]/tenofovir disoproxil fumarate [TDF]) is indicated for use as a complete regimen for the treatment of adults infected with HIV-1 with no known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or FTC, and with a viral load less than or equal to 100,000 copies/mL. PM: https://pdf.hres.ca/dpd_pm/00053856.PDF; date October 17, 2019; DIN 02374129; fetched 2026-09-10 Product monograph ETRAVIRINE · General benefit 1 INDICATIONS INTELENCE® (etravirine), in combination with other antiretroviral agents, is indicated for: • the treatment of human immunodeficiency virus type 1 (HIV-1) infection in treatment- experienced adult and pediatric (from 6 to <18 years of age and weighing ≥30 kg) patients who have failed prior therapy and have HIV-1 strains resistant to multiple antiretroviral agents, including NNRTIs (see 4 DOSAGE AND ADMINISTRATION). PM: https://pdf.hres.ca/dpd_pm/00075096.PDF; date March 27, 2008; DIN 02306778; fetched 2026-09-10 Product monograph RILPIVIRINE HYDROCHLORIDE · General benefit 1 INDICATIONS EDURANT® (rilpivirine), in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment- naïve adult and pediatric patients 12 years of age and older (and weighing ≥35 kg) with HIV-1 RNA less than or equal to 100,000 copies/mL at the start of therapy. 1.1 Pediatrics Pediatrics (12 to <18 years of age and weighing at least 35 kg): The safety, efficacy and pharmacokinetics of Edurant has been established in antiretroviral treatment-naïve, HIV-1 infected pediatric subjects 12 to less than 18 years of age and weighing at least 35 kg (see 4.2 Recommended Dose and Dosage Adjustment, 10.3 Pharmacokinetics, Pediatrics and 14.1 Clinical Trials by Indication, Treatment-Naïve Pediatric Patients (12 years to less than 18 years of age)). PM: https://pdf.hres.ca/dpd_pm/00077884.PDF; date July 20, 2011; DIN 02370603; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26

INDICATIONS AND CLINICAL USE VEMLIDY is indicated for the treatment of chronic hepatitis B in adults with compensated liver disease (see WARNINGS AND PRECAUTIONS). Geriatrics (≥ 65 years of age) Clinical trials of VEMLIDY did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients (see ACTION AND CLINICAL PHARMACOLOGY). Pediatrics (< 18 years of age) Safety and effectiveness of VEMLIDY in pediatric patients less than 18 years of age have not been established. https://pdf.hres.ca/dpd_pm/00058101.PDF PM date: August 20, 2020 Source product: VEMLIDY; DIN 02464241; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

1 INDICATIONS BIKTARVY (bictegravir/emtricitabine/tenofovir alafenamide) is indicated as a complete regimen for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults and pediatric patients weighing ≥ 25 kg with no known substitution associated with resistance to bictegravir or tenofovir. 1.1 Pediatrics Pediatrics (weighing ≥ 25 kg): The safety and efficacy in pediatric patients weighing ≥ 25 kg are based on data from an open-label clinical study (see 8 ADVERSE REACTIONS and 14 CLINICAL TRIALS). Safety and efficacy of BIKTARVY in children weighing < 25 kg have not been established. 1.2 Geriatrics Geriatrics (≥ 65 years of age): No differences in safety or efficacy have been observed between elderly patients and adult patients < 65 years of age (see 8 ADVERSE REACTIONS and 14 CLINICAL TRIALS). https://pdf.hres.ca/dpd_pm/00080778.PDF PM date: July 10, 2018 Source product: BIKTARVY; DIN 02478579; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

1 INDICATIONS SYMTUZA® (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) is indicated as a complete regimen for: • the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg) and with no known mutations associated with resistance to the individual components of SYMTUZA®. For a description of the clinical data and dosing in support of this indication, refer to 4 DOSAGE AND ADMINISTRATION and 14 CLINICAL TRIALS. 1.1 Pediatrics Pediatrics (≥12 and <18 years of age with body weight ≥40 kg) Pediatrics (≥12 years of age with body weight ≥40 kg): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of SYMTUZA in pediatric patients has been established. Therefore, Health Canada has authorized an indication for pediatric use. (see 4 DOSAGE AND ADMINISTRATION and 7 WARNINGS AND PRECAUTIONS). 1.2 Geriatrics Geriatrics (≥65 years of age) Limited information is available on the use of SYMTUZA® in patients aged 65 and over (see 4 DOSAGE AND ADMINISTRATION, 7 WARNINGS AND PRECAUTIONS, and 10 CLINICAL PHARMACOLOGY)… https://pdf.hres.ca/dpd_pm/00069792.PDF PM date: March 07, 2018 Source product: SYMTUZA; DIN 02473720; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

1 INDICATIONS GENVOYA (150 mg elvitegravir/150 mg cobicistat/200 mg emtricitabine/10 mg tenofovir alafenamide) is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing ≥ 25 kg and with no known mutations associated with resistance to the individual components of GENVOYA. 1.1 Pediatrics Pediatrics (weighing ≥ 25 kg): The safety and efficacy in children weighing ≥ 25 kg are based on data from an open-label clinical study (see 8 ADVERSE REACTIONS and 14 CLINICAL TRIALS). Pediatrics (weighing < 25 kg): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for use in pediatrics weighing < 25 kg. 1.2 Geriatrics Geriatrics (≥ 65 years of age): No differences in safety or efficacy have been observed between elderly patients and adult patients < 65 years of age (see 10 CLINICAL PHARMACOLOGY). https://pdf.hres.ca/dpd_pm/00062412.PDF PM date: November 27, 2015 Source product: GENVOYA; DIN 02449498; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

1. INDICATIONS ODEFSEY (emtricitabine [FTC]/rilpivirine [RPV]/tenofovir alafenamide [TAF]) is indicated as a complete regimen for the treatment of adults infected with HIV-1 with no known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or FTC, and with a viral load ≤ 100,000 copies/mL. The safety and efficacy of ODEFSEY has not been established in patients with a prior history of virologic failure. The following points should be considered prior to the initiation of therapy in patients with no antiretroviral treatment history:  Regardless of HIV-1 RNA at the start of therapy, more RPV-treated patients with CD4+ cell count less than 200 cells/mm3 at the start of therapy experienced virologic failure compared to patients with CD4+ cell count greater than or equal to 200 cells/mm3.  The observed virologic failure rate in RPV-treated patients conferred a higher rate of overall treatment resistance and cross-resistance to the NNRTI class compared to the control (efavirenz) (see WARNINGS AND PRECAUTIONS, Resistance/Cross- resistance, MICROBIOLOGY, Resistance… https://pdf.hres.ca/dpd_pm/00053935.PDF PM date: November 13, 2019 Source product: ODEFSEY; DIN 02461463; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.